13.61
-0.16
(-1.16%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 13.44 - 13.78 |
| 52 week | 9.19 - 16.95 |
| Open | 13.78 |
| Vol / Avg. | 28,280.00/169,827.00 |
| Mkt cap | 580.04M |
| P/E | - |
| Div/yield | - |
| EPS | -1.13 |
| Shares | 42.62M |
| Beta | - |
| Inst. own | 38% |
Events
May 14, 2013
ChemoCentryx Inc at Bank of America Merrill Lynch Health Care Conference
May 13, 2013
Q1 2013 ChemoCentryx Inc Earnings Conference Call
Mar 13, 2013
Q4 2012 ChemoCentryx Inc Earnings Conference Call
Mar 5, 2013
ChemoCentryx Inc at Cowen Health Care Conference
Feb 27, 2013
ChemoCentryx Inc at RBC Capital Markets' Healthcare Conference
Feb 25, 2013
ChemoCentryx Inc at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -528.96% | -736.13% |
| Operating margin | -534.09% | -731.32% |
| EBITD margin | - | -720.39% |
| Return on average assets | -34.72% | -35.64% |
| Return on average equity | -38.28% | -42.83% |
| Employees | 61 | - |
| Carbon Disclosure Rating | - | - |
Address
850 Maude Avenue
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Advertisement
Description
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�s wholly owned subsidiary is ChemoCentryx Limited.
Officers and directors
| Thomas J. Schall Ph.D. | Chairman of the Board, President, Chief Executive Officer | |
| Susan M. Kanaya | Chief Financial Officer, Senior Vice President - Finance, Secretary | |
| Juan C. Jaen Ph.D. | Senior Vice President - Drug Discovery, Chief Scientific Officer | |
| Petrus J. Bekker M.D., Ph.D. | Senior Vice President - Clinical and Medical Affairs | |
| Markus J. Cappel Ph.D. | Chief Business Officer, Treasurer | |
| Roger C. Lucas Ph.D. | Lead Independent Director | |
| Joseph M. Feczko M.D. | Independent Director | |
| Geoffrey M. Parker | Independent Director | |
| Edward E. Penhoet Ph.D. | Independent Director | |
| James L. Tyree | Independent Director |